MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Biogen Inc

Fermé

SecteurSoins de santé

130.65 -0.48

Résumé

Variation du prix de l'action

24h

Actuel

Min

130

Max

132.92

Chiffres clés

By Trading Economics

Revenu

-122M

267M

Ventes

-15M

2.5B

P/E

Moyenne du Secteur

12.24

63.778

BPA

3.44

Marge bénéficiaire

10.865

Employés

7,605

EBITDA

-158M

536M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+46.54% upside

Dividendes

By Dow Jones

Prochains Résultats

23 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-982M

20B

Ouverture précédente

131.13

Clôture précédente

130.65

Sentiment de l'Actualité

By Acuity

47%

53%

173 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Biogen Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 sept. 2024, 11:00 UTC

Actualités

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29 mai 2024, 15:56 UTC

Résultats
Acquisitions, Fusions, Rachats

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

Comparaison

Variation de prix

Biogen Inc prévision

Objectif de Prix

By TipRanks

46.54% hausse

Prévisions sur 12 Mois

Moyen 192.43 USD  46.54%

Haut 265 USD

Bas 135 USD

Basé sur 25 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

25 ratings

13

Achat

12

Maintien

0

Vente

Score Technique

By Trading Central

N/A / 141.43Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

173 / 386Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.